A carregar...
Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
Ruxolitinib improves splenomegaly and other disease-related symptoms in patients with myelofibrosis, but over time, many patients lose this benefit. It is difficult to determine whether this is due to resistance or intolerance to the drug; thus, we have used the more inclusive term of ruxolitinib fa...
Na minha lista:
| Publicado no: | JCO Oncol Pract |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7359776/ https://ncbi.nlm.nih.gov/pubmed/32134707 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.19.00506 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|